Physician profile
Edward Ewald
NPI 1497732564
$6,100.55
in general payments reported to CMS, 2019-2025
40 companies · $909 in 2025
The $909 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $559 · 2021: $1,004 · 2022: $1,108 · 2023: $994 · 2024: $1,002 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904 · Education: $1.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.10 |
| Education | $1.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.70 | 2021-2025 | |
| Novo Nordisk INC | $814.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $749.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $663.98 | 2019-2025 | Breztri, Bevespi Aerosphere, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.56 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $329.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $209.32 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.10 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $164.85 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $163.21 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $158.29 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astellas Pharma US INC | $146.58 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $128.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $105.93 | 2021-2025 | |
| Esperion Therapeutics, INC. | $91.16 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ewald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.